{"title":"成人多型胶质母细胞瘤预后因素的回顾性分析:单一机构经验","authors":"M. Moumen, L. E. E. Arab, N. Mosalam, A. Gaballah","doi":"10.21608/RESONCOL.2019.6360.1071","DOIUrl":null,"url":null,"abstract":"Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience\",\"authors\":\"M. Moumen, L. E. E. Arab, N. Mosalam, A. Gaballah\",\"doi\":\"10.21608/RESONCOL.2019.6360.1071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.\",\"PeriodicalId\":33915,\"journal\":{\"name\":\"Research in Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/RESONCOL.2019.6360.1071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/RESONCOL.2019.6360.1071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience
Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.